Nuclear Medicine: Page 103

Lantheus, GE finalize license agreement
By AuntMinnie.com staff writers
Lantheus Medical Imaging has signed a definitive agreement with GE Healthcare to support the worldwide development and commercialization of its flurpiridaz F-18 investigational PET radiopharmaceutical. The firms are also continuing their current supply agreement for other nuclear medicine products.
April 24, 2017
PET plays key role in preventive Alzheimer's study
By Wayne Forrest
With projections that the number of people living with Alzheimer's disease in the U.S. could more than triple by the year 2050, 65 research institutions are collaborating on a clinical trial using PET scans to identify the disease in its earliest stages, as well as guide the use of potential therapeutic agents.
April 18, 2017
2017 04 14 16 09 55 745 Amyloid Plaque Alzheimer 400
Cardinal Health provides cautionary fiscal outlook
By AuntMinnie.com staff writers
Hurt by price deflation from generic drugs, Cardinal Health said that fiscal 2017 profitability will be at the lower end of its previous guidance range. It also said that profit in its pharmaceutical segment could decline in fiscal 2018.
April 17, 2017
AuntMinnie.com Molecular Imaging Insider
By Wayne Forrest
April 16, 2017
PET links midlife vascular risk factors to more amyloid
By Wayne Forrest
Florbetapir-PET scans show that midlife adults with two or more vascular risk factors are significantly more likely to have greater levels of amyloid deposits in their brains later in life than peers with no such risk factors, according to a study published April 11 in the Journal of the American Medical Association.
April 11, 2017
2016 11 18 14 35 05 354 Brain Puzzle 400
PET reveals Alzheimer's risk factors | Doctor survey baffles breast screening skeptics | Immediate DBT reads
By Brian Casey
April 10, 2017
Immuno-PET radiotracers may aid cancer treatment
By AuntMinnie.com staff writers
Researchers at Stanford University are assessing how well new PET radiopharmaceuticals, called immuno-PET tracers, can accurately identify molecules in cancer cells that prevent the immune system from attacking the disease, according to a study published in the April issue of the Journal of Nuclear Medicine.
April 6, 2017
SNMMI offers appropriate use criteria for 2 cancers
By AuntMinnie.com staff writers
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria for bone scintigraphy in patients with prostate or breast cancer.
April 6, 2017
IBA Molecular forms Curium as new radiopharmacy player
By Erik L. Ridley
Radiopharmacy vendor IBA Molecular has combined with recent acquisition Mallinckrodt Nuclear Medicine to form Curium, a new company with a mission to be a global developer, manufacturer, and supplier of SPECT, PET, and therapeutic radiopharmaceuticals.
April 5, 2017
2016 09 13 17 07 43 134 Atomic Technology 400
GE awarded HealthTrust purchasing deal
By AuntMinnie.com staff writers
GE Healthcare will provide SPECT and PET radiopharmaceuticals to members of the HealthTrust group purchasing organization across the U.S.
April 5, 2017
Reduced FDG dose levels for PET/MRI show mixed results
By Wayne Forrest
Even though a lower dose of FDG did not significantly affect lesion detection for most adult cancer patients undergoing a whole-body PET/MRI scan, German researchers recommend that clinicians stay with recommended levels to avoid artifacts, according to a study published in the Journal of Nuclear Medicine.
April 5, 2017
2017 04 05 16 09 06 963 Pet Mri Fdg Dose Jnm Image B 200
PET identifies cell mutations in NSCLC patients
By AuntMinnie.com staff writers
With the help of FDG-PET and an advanced image analysis technique known as radiomics, researchers have identified genetic cell mutations that can cause non-small cell lung cancer (NSCLC), according to a study published in the April issue of the Journal of Nuclear Medicine.
April 3, 2017
2017 04 04 10 00 30 308 Pet Nsclc Jnm Image 500
Previous Page
Page 103 of 445
Next Page